Medical News

RSS

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Questions circle over health reform's effect on rising costs

"The White House has started to aggressively push back against a growing narrative that pending health reform legislation doesn't do enough to control spiraling health costs," Politico reports. Peter Orszag said reporters who go "on buzz and sort of loose talk," instead of doing "the hard work," were partly to blame for the pending narrative.

1 Dec 2009

Ekkyo publishes positive results from its LASH treatment study

A Multi-Center Clinical Study Started in 2007 Confirms That the Results of Physiological Scarring After Surgery can be Improved by Using the LASH(R) (Laser Assisted Skin Healing) Treatment. This New Therapeutic Approach is Based on the EkkyLite(TM) System and is the First Device to Improve Scarring. it has been Developed and is Sold by Ekkyo.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

Unemployed who are losing COBRA subsidy face dramatically higher insurance payments

The temporary federal subsidy program that helped thousands of unemployed people cover the costs of their health insurance is coming to a close, but government officials are looking for ways to continue it.

1 Dec 2009

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

TriCore Reference Laboratories of Albuquerque, N.M., reported at a recent user meeting results of their research collaboration with Roche Applied Science in which they evaluated Roche´s new MagNA Pure 96 System for use in nucleic acid purification. The evaluation focused on the Roche system’s ability to process specimens for pathogen testing.

1 Dec 2009

'Budget reconciliation' still part of health bill strategy discussions

Talk about using budget reconciliation to pass healthcare reform in the Senate has faded from public view, but Democratic leaders continue to hang the threat over centrists in private. Senate Majority Leader Harry Reid (D-Nev.) discussed reconciliation with wavering centrists before an important procedural vote to begin debate on healthcare reform.

1 Dec 2009

Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate

Palatin Technologies, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate.

1 Dec 2009

NIH Library subscribes to Computable Genomix' GeneIndexer

Memphis-based Computable Genomix today announced that the National Institutes of Health Library has purchased a subscription to its premier product, GeneIndexer, an online genomics research tool.

1 Dec 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Ardea Biosciences, Inc. announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This

1 Dec 2009

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

Trellis Bioscience, Inc. announced today the granting of a worldwide exclusive license to MedImmune, LLC, the global biologics unit of AstraZeneca, to develop and commercialize Trellis’ antibodies directed against the respiratory syncytial virus (RSV).

1 Dec 2009

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

ADVENTRX Pharmaceuticals, Inc. today announced that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere® (docetaxel). Shin Poong Pharmaceuticals, ADVENTRX's partner for ANX-514 in South Korea, independently conducted the study and data analysis.

1 Dec 2009

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Tianyin Pharmaceutical Co., Inc.,, a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA approval number Z20090855).

1 Dec 2009

Sentinelle Medical showcases its new line of breast MRI coils at the RSNA meeting

Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and 4D advanced visualization software, extends its line of award winning breast coils at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A).

1 Dec 2009

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

1 Dec 2009

Drug risk disclosures not read due to information overload, condensed version needed

When it comes to risk disclosures made by drug companies in print and television ads, many consumers are not paying attention, according to a recent study by ORC Guideline (an infoGROUP company). The latest study in the company’s Under the Skin series found that 41% of US consumers pay little or no attention to risk information presented by pharmaceutical companies in their TV commercials, and only half (50%) pay attention to such disclosures in print ads. This lack of attention is most prevalent among those 55 years of age or older.

1 Dec 2009

Royal Philips Electronics highlights its interventional radiology/oncology solutions at the RSNA meeting

On display at this year's Radiological Society of North America (RSNA) annual meeting, Royal Philips Electronics is highlighting its portfolio in the field of interventional radiology/oncology. The company is developing innovative image-guidance technologies for increasing the range and quality of minimally-invasive interventions and therapies.

From Philips Healthcare 1 Dec 2009

Driscoll Children's Hospital implements the CAREt bedside medication administration system

PatientSafe Solutions, Inc., formerly IntelliDOT(TM) Corporation, an industry expert in patient safety systems for hospitals, announced today an agreement to deploy its innovative bedside medication administration system, CAREt System, at Driscoll Children's Hospital, Corpus Christi, TX.

1 Dec 2009

FORMA Therapeutics closes Series B financing to a total of $25.5 million

FORMA Therapeutics today announced that it has closed on a Series B financing that raised a total of $25.5 million. The round was led by new investor Lilly Ventures, with participation from existing investors Novartis Option Fund and Bio*One Capital of Singapore.

1 Dec 2009

Medical News

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Questions circle over health reform's effect on rising costs

Ekkyo publishes positive results from its LASH treatment study

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Unemployed who are losing COBRA subsidy face dramatically higher insurance payments

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

'Budget reconciliation' still part of health bill strategy discussions

Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate

NIH Library subscribes to Computable Genomix' GeneIndexer

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Sentinelle Medical showcases its new line of breast MRI coils at the RSNA meeting

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Drug risk disclosures not read due to information overload, condensed version needed

Royal Philips Electronics highlights its interventional radiology/oncology solutions at the RSNA meeting

Driscoll Children's Hospital implements the CAREt bedside medication administration system

FORMA Therapeutics closes Series B financing to a total of $25.5 million

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News